Why Cervical Cancer Screening Rates Are Falling—and What Could Help Reverse the Trend
Despite effective prevention tools, Millennials are delaying screening. New approaches may help remove barriers to participation.
Despite effective prevention tools, Millennials are delaying screening. New approaches may help remove barriers to participation.
From assay validation to staffing and supply chain planning, labs can take steps to manage testing surges during flu and RSV season.
A longitudinal study finds blood-based biomarkers more sensitive than PET scans in detecting obesity's impact on Alzheimer's pathology.
The test can now be used to identify HER2-positive metastatic breast cancer patients that could be eligible for Enhertu.
The rapid PCR test delivers results up to 75% faster than other point-of-care HCV diagnostics, enabling same-day treatment initiation.
The cobas BV/CV assay aims to improve diagnostic accuracy over traditional microscopy and pH testing methods for symptomatic patients.
The gene expression test is designed to identify patients more likely to respond to JAK inhibitors versus Th2-targeted therapies.
The test measures two sugar alcohols to detect SORD-related neuropathy, which standard genetic tests sometimes miss.
Licensing agreement will integrate ALZpath's pTau217 antibody into Siemens' Atellica analyzer test menu for IVD Alzheimer's diagnostics.
The automated system uses ion exchange HPLC technology to deliver A1c results while detecting common hemoglobin variants.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The eight-minute test also shortened hospital stays by nearly two days at Froedtert Hospital, reinforcing previous multi-site evidence.